Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rheumatoid Arthritis: A Brief Overview of the Treatment.
Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Bullock J, et al. Med Princ Pract. 2018;27(6):501-507. doi: 10.1159/000493390. Epub 2018 Sep 2. Med Princ Pract. 2018. PMID: 30173215 Free PMC article. Review.
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial.
Allegretti JR, Kelly CR, Louie T, Fischer M, Hota S, Misra B, Van Hise NW, Yen E, Bullock JS, Silverman M, Davis I, McGill SK, Pardi DS, Orenstein R, Grinspan A, El-Nachef N, Feuerstadt P, Borody TJ, Khanna S S, Budree S, Kassam Z. Allegretti JR, et al. Among authors: bullock js. Gastroenterology. 2024 Oct 2:S0016-5085(24)05536-7. doi: 10.1053/j.gastro.2024.09.030. Online ahead of print. Gastroenterology. 2024. PMID: 39366468
Oncology Combination Drug Development Strategies for Project Optimus.
Yap TA, Bullock J, Chong S, Doyle MK, Hussain A, Kline J, Manon A, Venkatakrishnan K, Upreti VV. Yap TA, et al. Among authors: bullock j. Clin Cancer Res. 2024 Oct 4. doi: 10.1158/1078-0432.CCR-24-1836. Online ahead of print. Clin Cancer Res. 2024. PMID: 39365679
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Sands BE, et al. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. N Engl J Med. 2024. PMID: 39321363 Clinical Trial.
512 results